No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 144,131 | 157,708 | 118,077 | 134,219 | 138,160 | 162,019 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 45,489 | 44,367 | 24,152 | 25,947 | 27,260 | 23,676 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Founded in 1998 and headquartered in Chuncheon, South Korea, Boditech Med Inc. specializes in the development of in-vitro diagnostic solutions and reagents. The company's diverse product portfolio includes a range of advanced immunoassay analyzers designed to quantify analytes in various biological samples like blood, urine, and other body fluids. Key offerings include the ichroma II, an automated or semi-automated system for precise analyte measurement; AFIAS-6 and AFIAS-1, automated fluorescent immunoassay systems also designed for accurate quantification of targeted analytes; and the ichroma-50, an automatic immunoassay analyzer that determines analyte concentrations in bodily fluids. Additionally, the ichroma M2 is a portable analyzer suited for centralized hospital laboratories and physician's clinics, compatible with in-vitro diagnostic immunofluorescent assay kits for screening, monitoring, and routine examinations. Beyond these, Boditech Med also provides specialized diagnostic instruments such as the Ichroma TRIAS Reader, which measures targeted analyte concentration from diverse samples including blood, nasal, and nasopharyngeal swabs; the Hemochroma PLUS for quantitative total hemoglobin testing in blood; the i-chamber, an auxiliary component for ichroma systems; and the HandyRay, an innovative laser device facilitating needle-free capillary blood sampling. These diagnostic solutions address a broad spectrum of medical fields, including cardiac health, oncology, diabetes management, hormone analysis, infection, infectious diseases, gastrointestinal issues, and rheumatoid arthritis. Boditech Med Inc. distributes its products globally through a network of approximately 100 sales agencies.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Boditech Med Inc. (206640.KQ)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Founded in 1998 and headquartered in Chuncheon, South Korea, Boditech Med Inc. specializes in the development of in-vitro diagnostic solutions and reagents. The company's diverse product portfolio includes a range of advanced immunoassay analyzers designed to quantify analytes in various biological samples like blood, urine, and other body fluids. Key offerings include the ichroma II, an automated or semi-automated system for precise analyte measurement; AFIAS-6 and AFIAS-1, automated fluorescent immunoassay systems also designed for accurate quantification of targeted analytes; and the ichroma-50, an automatic immunoassay analyzer that determines analyte concentrations in bodily fluids. Additionally, the ichroma M2 is a portable analyzer suited for centralized hospital laboratories and physician's clinics, compatible with in-vitro diagnostic immunofluorescent assay kits for screening, monitoring, and routine examinations. Beyond these, Boditech Med also provides specialized diagnostic instruments such as the Ichroma TRIAS Reader, which measures targeted analyte concentration from diverse samples including blood, nasal, and nasopharyngeal swabs; the Hemochroma PLUS for quantitative total hemoglobin testing in blood; the i-chamber, an auxiliary component for ichroma systems; and the HandyRay, an innovative laser device facilitating needle-free capillary blood sampling. These diagnostic solutions address a broad spectrum of medical fields, including cardiac health, oncology, diabetes management, hormone analysis, infection, infectious diseases, gastrointestinal issues, and rheumatoid arthritis. Boditech Med Inc. distributes its products globally through a network of approximately 100 sales agencies.
